Budesonide/Glycopyrronium/Formoterol: A Review in COPD

Heo, Young-A

doi:10.1007/s40265-021-01562-6

“…In addition to routine clinical assessment, an important step in COPD patient management is to obtain reliable and effective information about the impact of COPD on their health conditions, including the daily symptoms of the disease, activity limitations, degrees of dyspnea, and other relevant information [ 18 ]. CAT Rating Scale is a short and simple questionnaire for COPD assessment.…”

Section: Discussion and Analysismentioning

confidence: 99%

Analyzing the Treatment of Patients with Acute Exacerbation of COPD with the Aid of Intelligent Diagnosis Method

Jiang

¹

,

Zhao

²

,

Song

³

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

To observe the clinical efficacy of heat clearing phlegm mixture combined with vibration sputum excretion instrument in the treatment of patients with acute exacerbation of COPD with phlegm-heat obstructing lung, 90 patients with acute exacerbation of COPD are selected and divided into three groups, namely, control group, traditional medicine group, and combined group: the control group (conventional western medicine treatment), traditional medicine group (heat clearing and phlegm mixture), and combined group (heat clearing and phlegm mixture + vibratory sputum excretion instrument) with 30 cases each. All the patients in the three groups were given conventional western medicine treatment. On this basis, the traditional medicine group was given the oral administration of the heat-clearing and phlegm-clearing mixture, and the combined group was given the oral administration of the heat-clearing and phlegm-clearing mixture and the vibratory sputum discharge apparatus. Machine learning is used to classify the patients into three groups based on the characteristics of their biomarkers, physical attributes, and medical history. The TCM syndrome score, blood gas analysis, lung function, and inflammatory indexes of the three groups were compared. TCM syndrome scores of the three groups were all lower than before; both the combined group and the TCM group were better than the control group ( P < 0.05). Although the improvement degree of the combined group was better than that of the TCM group, the difference was not statistically significant ( P > 0.05). TCM syndrome effect is seen to be 96.55% in the combined group, 89.29% in the TCM group, and 63.33% in the control group. Blood gas analysis is also performed; PO2 and PCO2 of the three groups were significantly improved after treatment. The combination group was superior to the traditional medicine group and the control group ( P < 0.05), and the traditional medicine group was superior to the control group ( P < 0.05). It is concluded that the combination of heat clearing phlegm mixture and vibration sputum excretion instrument can improve TCM syndrome score, CAT score, blood gas analysis, lung function, and inflammatory indicators in patients with acute exacerbation of COPD with phlegm-heat obstructing lung.

show abstract

“…Effective pharmacotherapy can be crucial in the treatment and prognosis of ARDS to enhance survival and shorten mechanical ventilation time [ 5 ]. Breztri Aerosphere, composed of budesonide/glycopyrronium bromide/formoterol, is a triple combination of the glucocorticoid budesonide, the long-acting β 2 agonist formoterol fumarate, and the long-acting cholinergic receptor antagonist glycopyrronium bromide [ 6 ]. The combination of the three drugs with different mechanisms of action potentiates their efficacy, with well-recognized efficacy in the treatment of chronic obstructive pulmonary disease (COPD); however, the efficacy of the drug for ARDS is poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Liu

¹

,

Wang

²

,

Ren

³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). Methods. A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group). Results. Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment. Conclusion. Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.

show abstract

“…e most common adverse reaction of glycopyrronium bromide was dry mouth, but most of them were mild rather than severe; other common adverse reactions include gastrointestinal reactions (including gastroenteritis and dyspepsia), local adverse reactions (laryngitis, rhinitis, rhinitis, and sinusitis), eye problems (pupil dilation and blurred vision), palpitation and arrhythmia (atrial fibrillation * ), urinary symptoms (urinary tract infection, dysuria, and urinary retention), and limb pain, chest pain, caries, rash, headache, insomnia, and cognitive impairment [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

[Retracted] The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Guo

¹

,

Chen

²

,

Li

³

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. Chronic obstructive pulmonary disease (COPD) is a major and difficult disease of the chronic respiratory system that is common and frequent, with a huge disease burden. The aim of this study was to investigate the efficacy and safety of budesonide/glyburide/formoterol fumarate (BGF) in the treatment of COPD. Methods. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The basic features of the seven pieces of literature were identified using the search strategy. The sample size range was 130∼1264. Results. The effects of BGF increased FEV1 in patients with COPD (mean difference = 2.86, 95%CI: 2.71–3.01, p < 0.00001 ). The effects of BGF improved in patients with ≥1 TEAE in patients with COPD, and was not statistically significant after treatment (Odds rate = 1.00, 95%CI: 0.85–1.17, p = 0.97 ). The effects of BGF increased in patients with TEAEs related a to study treatment in patients with COPD (odds rate = 1.27, 95% CI: 1.03–1.57, p = 0.02 ). The effects of BGF in decreased patients with serious TEAEs in patients with COPD (odds rate = −0.02, 95% CI: −0.03–−0.00, p = 0.04 ). The effects of BGF decreased the death rate in patients with COPD, and were not statistically significant after treatment (odds rate = 0.77, 95% CI: 0.31–1.97, p = 0.59 ). The effects of BGF decreased the hypertension rate in patients with COPD (odds rate = 0.92, 95% CI: 0.44–1.89, p = 0.81 ), and was not statistically significant after treatment. The effects of BGF increased pneumonia in patients with COPD (odds rate = 1.55, 95% CI: 0.81–2.97, p = 0.19 ), and were not statistically significant after treatment. The effects of BGF increased FEV1, increased patients with TEAEs related a to study treatment, and decreased patients with serious TEAEs in patients with COPD. Conclusion. This study elucidates the efficacy and safety of BGF in the treatment of COPD with a view to providing a clinical reference.

show abstract

Budesonide/Glycopyrronium/Formoterol: A Review in COPD

Cited by 20 publications

References 36 publications

Analyzing the Treatment of Patients with Acute Exacerbation of COPD with the Aid of Intelligent Diagnosis Method

Analyzing the Treatment of Patients with Acute Exacerbation of COPD with the Aid of Intelligent Diagnosis Method

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

[Retracted] The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Contact Info

Product

Resources

About